Scancell Holdings plc (AIM:SCLP)
London · Delayed Price · Currency is GBP · Price in GBX 12.45
+0.05 (0.40%)
Mar 4, 2026, 4:22 PM GMT
Scancell Holdings Employees
Scancell Holdings had 60 employees as of April 30, 2025. The number of employees decreased by 1 or -1.64% compared to the previous year.
Employees
60
Change (1Y)
-1
Growth (1Y)
-1.64%
Revenue / Employee
78.52K GBP
Profits / Employee
-91.85K GBP
Market Cap
129.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Apr 30, 2025 | 60 | -1 | -1.64% |
| Apr 30, 2024 | 61 | 10 | 19.61% |
| Apr 30, 2023 | 51 | 11 | 27.50% |
| Apr 30, 2022 | 40 | 15 | 60.00% |
| Apr 30, 2021 | 25 | 3 | 13.64% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| hVIVO | 301 |
| Avacta Group | 151 |
| 4basebio | 110 |
| PureTech Health | 56 |
| Arecor Therapeutics | 44 |
| Faron Pharmaceuticals Oy | 32 |
| Hemogenyx Pharmaceuticals | 16 |
| Poolbeg Pharma | 16 |
Scancell Holdings News
- 4 weeks ago - Scancell Holdings plc (SCNLF) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire
- 2 months ago - Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript - Seeking Alpha
- 6 months ago - Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 8 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire
- 2 years ago - PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free - Business Wire